On Wednesday, Shares of Alibaba Group Holding Ltd (NYSE:BABA), lost -1.18% to $84.99.
Alibaba Group Holding Limited is a holding company.
The company generates revenue of $12.62 billion. Its 52-Week low range is $57.20 and 52-week high range is $111.68. Its price to earnings (P/E) ratio stands at 32.79. The price range of the company is from $84.25 to $85.82 with the earning per share (EPS) is $2.59.
The year-to-date performance reflected a -18.22% below last year. During the past month the stock gains 29.69% bringing three-month performance to 29.69% and six-month performance to -6.17% . If we take a look on its volatility, 2.34% was seen in a week and for the month it was 3.01%.
Chinese e-commerce giant Alibaba Group Holding Ltd (NYSE:BABA), is unlikely to be interested in buying Yahoo Incs (YHOO.O) core business, the Wall Street Journal stated.
Yahoos board, in a three-day meeting that started on Wednesday, is weighing a sale of the companys Internet business, Reuters stated on Tuesday, citing a person familiar with the matter.
Board members are also predictable to discuss the details of the planned spinoff of Yahoos 15 percent stake in Alibaba, worth more than $30 billion.
Alibaba will be interested in repurchasing its shares from Yahoo only at a steep discount, the WSJ said on Thursday, citing a person familiar with the matter.
The Company is principally engaged in online and mobile commerce through products, services and technology. The Company provides retail and wholesale marketplaces available through both personal computer and mobile interfaces in the PRC and internationally. Retail marketplaces and services operated by the Company comprise the China online shopping destination (Taobao Marketplace); the China brands and retail platform (Tmall); the China group buying site that offers products by aggregating demand from consumers through limited time discounted sales (Juhuasuan), and the global consumer marketplace targeting consumers around the world (AliExpress).
Shares of Advanced Micro Devices, Inc (NASDAQ:AMD), declined -2.99% to $2.27, during its last trading session.
Advanced Micro Devices, Inc. is a global semiconductor company with facilities across the world. Recently at Autodesk University 2015, AMD (NASDAQ: AMD) unveiled the AMD FirePro™ W4300 for the best Computer-Aided Design (CAD) performance that fits both small form factor (SFF) and tower workstations.1 The AMD FirePro W4300 card expertly integrates a powerful GPU and 4GB of GDDR5 memory within a low-profile design for installation in SFF in addition to full-sized systems. Organizations can now confidently simplify their IT administration by standardizing on a single, capable professional graphics solution throughout their workstation deployment.
The AMD FirePro W4300 professional graphics card is optimized for the latest CAD applications counting Autodesk® AutoCAD, Inventor in addition to Revit®, Dassault Systèmes SOLIDWORKS® and CATIA®, PTC Creo®, Siemens NX™, and many more. Engineering professionals can efficiently work with large geometry-intense models and apply GPU-accelerated features in their projects, such as the new Order Independent Transparency (OIT) mode supported in SOLIDWORKS. Users can assist improvement productivity by visualizing their workflows across up to six displays2, and up to 4K and 5K resolution.
The Company offers x86 microprocessors, as standalone devices or as incorporated as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs) and professional graphics, and server and embedded processors, dense servers, semi-custom System-on-Chip (SoC) products and technology for game consoles.
Finally, Relypsa Inc (NASDAQ:RLYP), ended its last trade with -0.25% loss, and closed at $24.06.
Relypsa, Inc. (RLYP) declared that John A. Orwin, president and chief executive officer, will present at the Oppenheimer 26th Annual Healthcare Conference on December 8, 2015 at 2:10 p.m. ET.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Companys lead product candidate, Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration, or FDA.
This article is published by www.stocksnewswire.com. The content included in this article is just for informational purposes only. Stocksnewswire.com takes sensible consideration to ensure that the data given in this article is up to date and accurate. The news, prices, opinions, research, analysis, and other information published in this article are obtained from sources believed to be reliable.
Neither Stocksnewswire.com nor any of Stocksnewswire.com partners make any representation or guarantee as to the fulfillment or precision of the information contained in this article.
Investors must consult their own additional due diligence with any potential investment or highlighted company before making any decision on behalf of information offered by Stocksnewswire.com.
Information contained in this article may contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long-term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.